PharVision Advisers’s Kinsale Capital Group KNSL Stock Holding History

PharVision Advisers’s Portfolio KNSL Stock Details KNSL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-474	Closed	-$202K	–	857
2025 Q3	$202K	Buy	+474	New	+$215K	0.11%	515

Other funds holding KNSL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LCIP

Life Cycle Investment Partners London $15.7B AUM

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

PharVision Advisers's KNSL Position: Q4 2025 in Review

PharVision Advisers sold out of Kinsale Capital Group (KNSL) in Q4 2025, closing a stake of 474 shares — an estimated $202K sold.

PharVision Advisers first reported a position in KNSL in Q3 2025 and held it in 1 quarter. The position peaked at $202K in Q3 2025. 590 funds tracked by Wall St. Rank hold KNSL as of Q4 2025.

PharVision Advisers reported no remaining Kinsale Capital Group position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 474 Kinsale Capital Group shares in Q4 2025, an estimated $202K.
PharVision Advisers first reported a position in Kinsale Capital Group in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Kinsale Capital Group position peaked at $202K in Q3 2025.
590 funds tracked by Wall St. Rank held Kinsale Capital Group as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.